HUTCHMED (China) Limited

Contributing Author

Recent Articles by HUTCHMED (China) Limited

17 hours	HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia HCM GlobeNewswire
Apr-08	HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 HCM GlobeNewswire
Mar-22	HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China HCM GlobeNewswire
Mar-09	HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK in China HCM GlobeNewswire
Mar-06	Intended Retirement of Independent Non-executive Director and changes of composition of board committees HCM GlobeNewswire
Mar-05	HUTCHMED Reports 2025 Full Year Results and Business Updates HCM GlobeNewswire
Mar-04	HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors HCM GlobeNewswire
Feb-06	HUTCHMED to Announce 2025 Final Results HCM GlobeNewswire
Jan-13	HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet HCM GlobeNewswire
Jan-06	HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China HCM +6.62% GlobeNewswire
Jan-04	HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma HCM GlobeNewswire
Dec-30	HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification HCM GlobeNewswire
Dec-29	HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma HCM GlobeNewswire
Dec-16	HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors HCM GlobeNewswire
Dec-07	HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China HCM GlobeNewswire
Nov-26	HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting HCM GlobeNewswire
Nov-04	HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS and TAGRISSO Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO HCM GlobeNewswire
Nov-02	HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event HCM GlobeNewswire
Oct-22	HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics HCM GlobeNewswire
Oct-14	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee HCM GlobeNewswire
Oct-13	HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress HCM GlobeNewswire
Oct-01	HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 HCM GlobeNewswire
Sep-11	Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 HCM +9.53% GlobeNewswire
Sep-04	HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 HCM +7.61% GlobeNewswire
Aug-24	HUTCHMED Announces Appointment of Acting Chief Executive Officer HCM GlobeNewswire
Aug-19	HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS and TAGRISSO Combination as a First-Line Therapy for Certain Lung Cancer Patients in China HCM GlobeNewswire
Aug-07	HUTCHMED Reports 2025 Interim Results HCM -9.01% GlobeNewswire
Jul-03	HUTCHMED to Announce 2025 Half-Year Financial Results HCM GlobeNewswire
Jun-30	HUTCHMED Announces China Approval for ORPATHYS in Combination with TAGRISSO for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy HCM GlobeNewswire
Jun-04	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma HCM GlobeNewswire
Jun-01	HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting HCM GlobeNewswire
May-22	HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting HCM GlobeNewswire

HUTCHMED (China) Limited

Recent Articles by HUTCHMED (China) Limited

Upgrade your Finviz experience